The table below shows IOVANCE BIOTHERAPEUTICS, INC.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
-$302.41M
-$352.98M
-$361.82M
-$292.76M
-$227.94M
-$205.13M
Capital expenditure
$33.84M
$11.07M
$22.29M
$20.43M
$37.57M
$46.79M
Investing cash flow
$47.50M
-$96.41M
-$155.24M
$256.45M
$132.00K
-$317.85M
Dividends paid
-
-
-
-
-
IOVA operating cash flow (10-K history)
IOVANCE BIOTHERAPEUTICS, INC. reported operating cash flow of -$302.41M for fiscal year 2025. That is up 14.3% from -$352.98M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$32.67M (FY 2016) to -$302.41M. Figures come from the company's audited annual reports as filed with the SEC.
